Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:57:31.671Z.
Calculation as of: 2026-10-06T16:57:31.671Z.
Quote observation: 2026-10-06T16:55:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$1.98B
EV/EBIT Ratio
34.71x
TTM Avg
44.12x
3Y Avg
112.76x
5Y Avg
112.76x
Market Cap
$2.02B
EV/EBIT Ratio
12.59x
TTM Avg
22.52x
3Y Avg
26.44x
5Y Avg
26.44x
Market Cap
$2.04B
EV/EBIT Ratio
N/A
TTM Avg
41.80x
3Y Avg
41.80x
5Y Avg
41.80x
Market Cap
$1.91B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.05B
EV/EBIT Ratio
272.92x
TTM Avg
247.10x
3Y Avg
123.52x
5Y Avg
99.39x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.97B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 34.71x | 44.12x | 112.76x | 112.76x |
| AxoGen, Inc. (AXGN)vs › | $1.96B | N/A | 408.25x | 408.25x | 408.25x |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 12.59x | 22.52x | 26.44x | 26.44x |
| Progyny, Inc. (PGNY)vs › | $2.04B | 17.08x | 21.63x | 33.37x | 79.37x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 41.80x | 41.80x | 41.80x |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.05B | 71.08x | 53.16x | 49.42x | 49.42x |
| Fortrea Holdings Inc. (FTRE)vs › | $2.05B | 272.92x | 247.10x | 123.52x | 99.39x |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | N/A | 4584.86x | 4584.86x | 4584.86x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
